Flow cytometric analysis of BCL-2 can distinguish small numbers of acute lymphoblastic leukaemia cells from B-cell precursors

被引:15
作者
Hartung, L
Bahler, DW [1 ]
机构
[1] Univ Utah, Med Ctr, Dept Pathol, Salt Lake City, UT 84132 USA
[2] Univ Utah, ARUP Inst Clin & Expt Pathol, Salt Lake City, UT 84132 USA
关键词
precursor B-cell acute lymphoblastic leukaemia; bcl-2; flow cytometry; minimal residual disease;
D O I
10.1111/j.1365-2141.2004.05155.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Flow cytometric identification of small numbers of precursor B-cell acute lymphoblastic leukaemia (B-ALL) cells in post-treatment marrow specimens could benefit from the identification of additional, easily detectable markers that could be used in most cases. In this study, we evaluate whether bcl-2 expression quantified by four-colour flow cytometry can be effectively used to discriminate precursor B-ALL blasts from normal B-cell precursors (haematogones) and function as a leukaemia-specific marker. Levels of bcl-2 in the 22 precursor B-ALL cases studied were found to be significantly higher (over sixfold higher on average) than those present in haematogone populations from 22 control marrow specimens. Higher relative levels of bcl-2 expression in the B-ALL cases were maintained with respect to both immature CD34(+) and more mature CD34(-) haematogone subsets, and appeared stable. Dilutional studies indicated that multiparameter flow cytometry analysis using bcl-2 could identify precursor B-ALL blasts representing as few as 1% of CD19(+) cells or 0.01% of total leucocytes in bone marrow specimens containing substantial numbers of haematogones. This study suggests that bcl-2 may be an important marker for flow cytometric detection and quantification of small numbers of residual precursor B-ALL cells in bone marrow specimens.
引用
收藏
页码:50 / 58
页数:9
相关论文
共 29 条
[1]  
Borowitz MJ, 1997, CYTOMETRY, V30, P236, DOI 10.1002/(SICI)1097-0320(19971015)30:5<236::AID-CYTO4>3.0.CO
[2]  
2-F
[3]   Determination of minimal residual disease in leukaemia patients [J].
Campana, D .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (06) :823-838
[4]  
Campana D, 1999, CYTOMETRY, V38, P139, DOI 10.1002/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO
[5]  
2-H
[6]  
CAMPANA D, 1993, BLOOD, V81, P1025
[7]  
Campos L, 1996, LEUKEMIA, V10, P434
[8]  
Casale F, 2003, INT J ONCOL, V22, P123
[9]   Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia [J].
Cavé, H ;
ten Bosch, JV ;
Suciu, S ;
Guidal, C ;
Waterkeyn, C ;
Otten, J ;
Bakkus, M ;
Thielemans, K ;
Grandchamp, B ;
Vilmer, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :591-598
[10]   Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia [J].
Chen, JS ;
Coustan-Smith, E ;
Suzuki, T ;
Neale, GA ;
Mihara, K ;
Pui, CH ;
Campana, D .
BLOOD, 2001, 97 (07) :2115-2120